MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.89% | 33.14% | 36.37% | 46.28% | 19.27% |
| Total Depreciation and Amortization | -37.51% | -35.64% | -34.53% | -22.85% | 1.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -31.59% | -95.50% | -46.07% | 133.35% | 130.29% |
| Change in Net Operating Assets | -94.57% | -120.28% | -129.18% | -162.38% | -52.65% |
| Cash from Operations | -9.84% | -191.46% | -47.24% | 43.94% | 61.32% |
| Capital Expenditure | 36.40% | 38.94% | 65.87% | 63.73% | 67.94% |
| Sale of Property, Plant, and Equipment | 712.04% | 519.31% | 55.75% | -99.22% | -72.88% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 984.30% | -5.58% | -37.90% | -102.01% | -93.93% |
| Total Debt Issued | -37.42% | -37.42% | -26.57% | -25.12% | -25.12% |
| Total Debt Repaid | 77.32% | 74.04% | -147.96% | -63.38% | -51.72% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -55.50% | -53.90% | -64.97% | -80.98% | -32.12% |
| Cash from Financing | 99.50% | 96.32% | -3,250.97% | -498.90% | -405.53% |
| Foreign Exchange rate Adjustments | 234.21% | 100.18% | 106.52% | 102.60% | 101.58% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 87.92% | -1,709.47% | -546.65% | -148.24% | 0.53% |